OK so here's the story....EARLY this morning I had a broker (Not my own sell me on (ANX)......He said just watch it and if It does good maybe we can do some other business later.....Pretty Sly way to get my attention.....So I was watching all day, bought 6K shares @ 4.50 after it made the first little move.....Didn't want to post it, because I was interested in this guys idea.....Never had a stranger try to pitch me a stock right before it pops 18%.....Hmmmmmm.....Good way to get business, but If you just spend all day pitching the same stock to the masses over the phone eventually the firm gets buyers and the price begins to move......
What does everyone think of this.....Did he/his firm know something the street didn't?.....Has this happened to anyone else?.......Don't get me wrong, I am happy. ANX is moving the right way, but is this a classic pump and dump scenario?....You gotta wonder how many people he/his firm called.....Funny thing was right after it popped my phone started ringing again.....I just laughed and took it off the hook.....Thanks but NO THANKS!!!!!
Sure enough look at the news that broke after the first leg up today.....
ADVENTRX Announces Thiovir Active Against H5N1 Avian Influenza Chimeric Virus Strains
Monday, March 20, 2006 2:26 PM
- PR Newswire
SAN DIEGO, March 20, 2006 /PRNewswire-FirstCall via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (ANX) announced today that it performed additional preclinical studies demonstrating that the Company's broad spectrum antiviral drug, Thiovir(TM), is active against a chimeric avian/human influenza virus and influenza A. Thiovir activity against these viruses was confirmed by preclinical tests conducted in-house and at two independent laboratories.
The chimeric viruses tested include a research-adapted strain based on influenza A/Vietnam/1203/04 (H5N1) and Ann Arbor/6/60. Influenza A/Vietnam/1203/04 is a highly pathogenic avian influenza strain characterized by elevated lethality to both humans and poultry. Cytopathic and direct viral detection-based assays were used to test Thiovir activity. ADVENTRX plans to further investigate Thiovir efficacy against multiple H5N1 strains of avian influenza in both in vitro and in vivo studies in collaboration with a Biosafety Level 3+ certified laboratory.
"We are encouraged by the results from two independent labs confirming Thiovir activity against multiple influenza viruses," said Evan M. Levine, president and CEO for ADVENTRX. "We will continue to investigate Thiovir as a therapy for influenza viruses, including bird flu, and we look forward to announcing additional results."
The Company plans to submit results from these and additional planned preclinical studies in the 14th International Symposium on HIV and Emerging Infectious Diseases program. The conference takes place June 21-23, 2006 in Toulon, France.
About Thiovir
Thiovir is a broad spectrum anti-viral and a non-nucleoside reverse transcriptase inhibitor (NNRTI) designed for oral delivery as a component of HAART. Thiovir is a prodrug for foscarnet that delivers both the active drug TPFA (thiophosphonoformate) and the active metabolite PFA (foscarnet) in an oral formulation. Thiovir is intended to deliver the benefits of the drug foscarnet, including broad spectrum antiviral activity, with the added benefit of improved bioavailability. ADVENTRX currently plans to file an investigational new drug application with the US Food and Drug Administration in the first half of 2006 for testing of Thiovir in patients with HIV/AIDS.
About ADVENTRX
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new anticancer and antiviral treatments that surpass the performance and safety of existing drugs by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. More information can be found on the Company's Web site at
www.adventrx.com .
$COSTAverageMAN
